Last reviewed · How we verify

PEG-ascorbate 2L — Competitive Intelligence Brief

PEG-ascorbate 2L (PEG-ascorbate 2L) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antioxidant/Vitamin derivative. Area: Oncology.

phase 3 Antioxidant/Vitamin derivative Ascorbate receptor (SVCT1/SVCT2) and general oxidative stress pathways Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PEG-ascorbate 2L (PEG-ascorbate 2L) — Parc de Salut Mar. PEG-ascorbate 2L is a polyethylene glycol-conjugated form of vitamin C designed to improve systemic delivery and bioavailability of ascorbate for antioxidant and potential anti-cancer effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PEG-ascorbate 2L TARGET PEG-ascorbate 2L Parc de Salut Mar phase 3 Antioxidant/Vitamin derivative Ascorbate receptor (SVCT1/SVCT2) and general oxidative stress pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antioxidant/Vitamin derivative class)

  1. Parc de Salut Mar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEG-ascorbate 2L — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-ascorbate-2l. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: